RI-002: Completed Phase III enrollment

ADMA completed enrollment of about 60 patients in an open-label, U.S. Phase III trial evaluating 300-800 mg/kg IV RI-002 every 21 or 28 days for 12 months. ADMA said RI-002 demonstrated improved produ...